Revance announces proposed public offering of common stock

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock. The Company intends to use the net proceeds received from its offering of common stock to continue to fund the commercialization of DAXI, and the remainder for working capital, research and development and general

19 Feb 2020 To the extent the underwriters exercise their option to purchase additional shares of common stock, the Company intends to use the net proceeds Revance Announces Proposed Private Offering Of $200 Mln Of Convertible Senior BRIEF-Revance Announces Proposed Public Offering Of Common Stock. 6 Feb 2020 miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock. Email Print Friendly Share. February Revance Announces Proposed Public Offering of Common Stock - Dec. 3, 2019. 12/3/2019. Revance Therapeutics, Inc. announced a proposed underwritten

Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement

Revance Therapeutics Announces Proposed Public Offering of Common Stock November 02, 2015 NEWARK, Calif. , Nov. 2, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,250,000 shares of its common stock. Revance Therapeutics, Inc. RVNC, -7.01% today announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to a registration statement filed with the NEWARK, Calif.,--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock.

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in which it will issue and sell approximately $175 million of shares of its common stock. In addition, certain stockholders of the Company (the "Selling Stockholders") are offering 600,000 shares of the Company's

NEWARK, Calif.,--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock. Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance” or the "Company”), today announced a proposed underwritten public offering in which it will issue and sell approximately $100 million of shares of its common stock. Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement NEWARK, Calif.,--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic RVNC, +0.29%, a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public offering of 5,882,353 shares of its common stock at a price to the public of $17.00 per share.

NEWARK, Calif.,--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic